Argent Biopharma (RGTLF) Ratios
Argent Biopharma Ratios
RGTLF's free cash flow for Q3 2025 was $-709.30K. For the 2025 fiscal year, RGTLF's free cash flow was increased by $0.00 and operating cash flow was $-709.30K. See a summary of the company’s cash flow.
| Ratios | Jun 25 | Jun 24 | Jun 23 | Jun 22 | Jun 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.05 | 0.19 | 0.23 | 0.18 | 0.89 |
| Quick Ratio | 0.05 | 0.18 | 0.15 | 0.09 | 0.65 |
| Cash Ratio | 0.02 | 0.09 | 0.06 | 0.02 | 0.20 |
| Solvency Ratio | -0.70 | -1.54 | -0.98 | -1.11 | -1.21 |
| Operating Cash Flow Ratio | -0.47 | -0.86 | 0.00 | 0.00 | 0.00 |
| Short-Term Operating Cash Flow Coverage | -0.54 | -1.17 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -10.28M | $ -9.07M | $ -13.87M | $ -15.59M | $ -5.50M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 7.40 | 3.36 | 0.10 | 0.06 | 0.19 |
| Debt-to-Equity Ratio | -1.02 | -0.96 | -0.20 | -0.08 | 0.39 |
| Debt-to-Capital Ratio | 67.01 | -24.18 | -0.25 | -0.08 | 0.28 |
| Long-Term Debt-to-Capital Ratio | -0.29 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -0.14 | -0.29 | -2.09 | -1.32 | 2.10 |
| Debt Service Coverage Ratio | -0.97 | -2.13 | -32.69 | -59.48 | -7.29 |
| Interest Coverage Ratio | -219.33 | -301.01 | -37.85 | -46.28 | -75.04 |
| Debt to Market Cap | 3.05 | 1.71 | 0.00 | 0.00 | 2.00 |
| Interest Debt Per Share | 0.11 | 0.15 | 0.04 | 0.31 | 1.79 |
| Net Debt to EBITDA | -1.31 | -0.43 | -0.02 | -0.02 | -0.16 |
| Profitability Margins | |||||
| Gross Profit Margin | -126.69% | 76.50% | 22.86% | 42.82% | 38.25% |
| EBIT Margin | -4586.90% | -3049.63% | -1915.19% | -613.85% | -358.17% |
| EBITDA Margin | -4484.80% | -2914.38% | -1770.00% | -591.65% | -352.94% |
| Operating Profit Margin | -4586.90% | -2646.84% | -2049.40% | -460.46% | -301.38% |
| Pretax Profit Margin | -4783.36% | -3058.43% | -1969.34% | -623.80% | -362.19% |
| Net Profit Margin | -4783.36% | -3058.43% | -1967.34% | -614.71% | -354.31% |
| Continuous Operations Profit Margin | -4783.36% | -3058.43% | -1969.34% | -623.86% | -362.19% |
| Net Income Per EBT | 100.00% | 100.00% | 99.90% | 98.54% | 97.82% |
| EBT Per EBIT | 104.28% | 115.55% | 96.09% | 135.47% | 120.18% |
| Return on Assets (ROA) | -595.44% | -723.12% | -162.51% | -210.75% | -71.18% |
| Return on Equity (ROE) | 81.63% | 206.77% | 340.24% | 277.42% | -149.25% |
| Return on Capital Employed (ROCE) | 102.03% | 184.66% | 1315.01% | 461.79% | -98.81% |
| Return on Invested Capital (ROIC) | -5166.99% | 4766.67% | 1567.67% | 489.40% | -85.48% |
| Return on Tangible Assets | -595.44% | -723.12% | -162.51% | -210.75% | -92.28% |
| Earnings Yield | -246.96% | -385.33% | -139.31% | -1726.83% | -1593.48% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.67 | 1.55 | 1.87 | 6.38 | 1.41 |
| Payables Turnover | 0.48 | 0.08 | 0.72 | 0.89 | 1.17 |
| Inventory Turnover | 0.00 | 1.03 | 0.79 | 1.54 | 1.31 |
| Fixed Asset Turnover | 1.59 | 1.33 | 0.13 | 0.45 | 0.49 |
| Asset Turnover | 0.12 | 0.24 | 0.08 | 0.34 | 0.20 |
| Working Capital Turnover Ratio | -0.02 | -0.06 | -0.09 | -0.57 | 0.00 |
| Cash Conversion Cycle | -219.90 | -4237.13 | 151.82 | -117.28 | 223.32 |
| Days of Sales Outstanding | 540.90 | 235.00 | 195.19 | 57.25 | 258.20 |
| Days of Inventory Outstanding | 0.00 | 353.15 | 464.69 | 237.35 | 277.75 |
| Days of Payables Outstanding | 760.80 | 4825.28 | 508.06 | 411.88 | 312.63 |
| Operating Cycle | 540.90 | 588.15 | 659.88 | 294.60 | 535.95 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.05 | -0.16 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Per Share | -0.05 | -0.16 | -0.39 | -3.83 | -5.79 |
| Dividend Paid and CapEx Coverage Ratio | -2493.85 | -4159.40 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | -2493.85 | -4159.40 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -0.42 | -1.12 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | -24.97 | -15.90 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -128.97% | -200.43% | -114.44% | -933.72% | -1411.20% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.40 | -0.26 | -0.72 | -0.06 | -0.06 |
| Price-to-Sales (P/S) Ratio | 19.37 | 7.94 | 14.12 | 0.36 | 0.22 |
| Price-to-Book (P/B) Ratio | -0.33 | -0.54 | -2.44 | -0.16 | 0.09 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.78 | -0.50 | -0.87 | -0.11 | -0.07 |
| Price-to-Operating Cash Flow Ratio | -0.78 | -0.50 | 0.00 | 0.00 | 0.00 |
| Price-to-Earnings Growth (PEG) Ratio | 0.01 | 0.01 | 0.01 | -0.01 | 0.00 |
| Enterprise Value Multiple | -1.74 | -0.70 | -0.82 | -0.08 | -0.22 |
| Enterprise Value | 12.57M | 11.89M | 12.93M | 1.54M | 3.66M |
| EV to EBITDA | -1.74 | -0.70 | -0.82 | -0.08 | -0.22 |
| EV to Sales | 77.98 | 20.39 | 14.51 | 0.45 | 0.77 |
| EV to Free Cash Flow | -3.12 | -1.28 | -0.90 | -0.14 | -0.25 |
| EV to Operating Cash Flow | -3.12 | -1.28 | 0.00 | 0.00 | 0.00 |
| Tangible Book Value Per Share | -0.11 | -0.15 | -0.16 | -2.77 | 1.76 |
| Shareholders’ Equity Per Share | -0.11 | -0.15 | -0.14 | -2.55 | 4.38 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | -0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.01 | 0.02 | 1.15 | 1.84 |
| Net Income Per Share | -0.09 | -0.31 | -0.47 | -7.08 | -6.53 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 0.99 | 0.98 |
| Interest Burden | 1.04 | 1.00 | 1.03 | 1.02 | 1.01 |
| Research & Development to Revenue | 3.04 | 6.16 | 2.61 | 0.59 | 0.00 |
| SG&A to Revenue | 41.56 | 13.81 | 9.73 | 3.58 | 1.97 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.52 | 2.50 | 0.00 | 0.00 | 0.00 |
Currency in AUD